O. Pate

711 total citations
13 papers, 581 citations indexed

About

O. Pate is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, O. Pate has authored 13 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in O. Pate's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Cancer Treatment and Pharmacology (5 papers). O. Pate is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Cancer Treatment and Pharmacology (5 papers). O. Pate collaborates with scholars based in United States. O. Pate's co-authors include Fernando Cabanillas, Jorge Romaguera, Peter McLaughlin, A H Sarris, Fredrick B. Hagemeister, F Swan, Anas Younes, M Keating, Maria Alma Rodriguez and Frederick Hagemeister and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

O. Pate

13 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Pate United States 9 380 284 280 78 78 13 581
Matteo Dell’Olio Italy 14 378 1.0× 286 1.0× 274 1.0× 77 1.0× 52 0.7× 30 624
L. J. Swinnen United States 11 255 0.7× 285 1.0× 653 2.3× 115 1.5× 86 1.1× 19 1.1k
J. P. Lamagnere France 10 146 0.4× 97 0.3× 137 0.5× 85 1.1× 39 0.5× 19 407
Ken Bradstock Australia 9 247 0.7× 210 0.7× 313 1.1× 105 1.3× 53 0.7× 15 630
Lisa Durkin United States 13 213 0.6× 245 0.9× 254 0.9× 234 3.0× 39 0.5× 32 626
W. Hiddemann Germany 2 871 2.3× 432 1.5× 627 2.2× 35 0.4× 140 1.8× 2 969
Manfred Welslau Germany 7 335 0.9× 228 0.8× 306 1.1× 65 0.8× 71 0.9× 28 501
Zhengzi Qian China 10 197 0.5× 89 0.3× 179 0.6× 120 1.5× 21 0.3× 29 415
Maria DeSantis Austria 8 126 0.3× 86 0.3× 244 0.9× 283 3.6× 29 0.4× 11 659
Isabelle Desbois France 12 96 0.3× 113 0.4× 136 0.5× 62 0.8× 27 0.3× 26 415

Countries citing papers authored by O. Pate

Since Specialization
Citations

This map shows the geographic impact of O. Pate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Pate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Pate more than expected).

Fields of papers citing papers by O. Pate

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Pate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Pate. The network helps show where O. Pate may publish in the future.

Co-authorship network of co-authors of O. Pate

This figure shows the co-authorship network connecting the top 25 collaborators of O. Pate. A scholar is included among the top collaborators of O. Pate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Pate. O. Pate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
3.
Cortes, Jörge E., Susan O’Brien, Srđan Verstovšek, et al.. (2004). Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.. Blood. 104(11). 1009–1009. 10 indexed citations
4.
Sarris, A H, Frederick Hagemeister, Jorge Romaguera, et al.. (2000). Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial. Annals of Oncology. 11(1). 69–72. 109 indexed citations
5.
McLaughlin, Paul, Fredrick B. Hagemeister, Maria Alma Rodriguez, et al.. (2000). Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.. PubMed. 27(6 Suppl 12). 37–41. 51 indexed citations
6.
Ayoub, Jean-Pierre, Andreas H. Sarris, F. B. Hagemeister, et al.. (1997). Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial. British Journal of Haematology. 96(2). 328–332. 31 indexed citations
7.
Younes, Anas, Maria Alma Rodriguez, Peter McLaughlin, et al.. (1997). Phase I Study of Fludarabine and Paclitaxel for the Treatment of Low-Grade Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 26(1-2). 77–82. 11 indexed citations
8.
Younes, Anas, Jean-Pierre Ayoub, A H Sarris, et al.. (1997). Paclitaxel (Taxol®) for the treatment of lymphoma. Annals of Oncology. 8. S129–S131. 5 indexed citations
9.
Younes, Anas, Jean-Pierre Ayoub, A H Sarris, et al.. (1997). Paclitaxel (Taxol) for the treatment of lymphoma.. PubMed. 8 Suppl 1. 129–31. 10 indexed citations
10.
Younes, Anas, Fernando Cabanillas, Peter W. McLaughlin, et al.. (1996). Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Annals of Oncology. 7(10). 1083–1085. 6 indexed citations
11.
McLaughlin, Peter, Fredrick B. Hagemeister, Jorge Romaguera, et al.. (1996). Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.. Journal of Clinical Oncology. 14(4). 1262–1268. 219 indexed citations
12.
McLaughlin, Peter, Fredrick B. Hagemeister, F Swan, et al.. (1994). Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.. Journal of Clinical Oncology. 12(3). 575–579. 77 indexed citations
13.
McLaughlin, Peter, F Swan, Fernando Cabanillas, et al.. (1994). Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Annals of Oncology. 5. S73–S77. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matteo Dell’Olio Breakdown of academic impact, for papers by L. J. Swinnen Breakdown of academic impact, for papers by J. P. Lamagnere Breakdown of academic impact, for papers by Ken Bradstock Breakdown of academic impact, for papers by Lisa Durkin Breakdown of academic impact, for papers by W. Hiddemann Breakdown of academic impact, for papers by Manfred Welslau Breakdown of academic impact, for papers by Zhengzi Qian Breakdown of academic impact, for papers by Maria DeSantis Breakdown of academic impact, for papers by Isabelle Desbois
Rankless by CCL
2026